Skip to main content
Clinical Trials/NCT05262621
NCT05262621
Completed
N/A

Effects of Music Intervention Combined With Progressive Muscle Relaxation on Anxiety, Depression and Quality of Life in Breast and Gynaecological Cancer Patients Receiving Chemotherapy: A Randomized Controlled Trial

The Nethersole School of Nursing1 site in 1 country84 target enrollmentMarch 8, 2022
ConditionsCancer

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cancer
Sponsor
The Nethersole School of Nursing
Enrollment
84
Locations
1
Primary Endpoint
Change from baseline anxiety at 3 weeks and 6 weeks
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

Study design A 2-arm, assessor-blinded randomised controlled trial will be conducted. The design will follow the Standard Protocol Items Recommendations for Interventional Trials (SPIRIT)

Detailed Description

Aim: To assess the effect of MCP on anxiety, depression and QoL of BGC patients receiving chemotherapy. Objectives * To assess the effect of MCP on the anxiety of BGC patients receiving chemotherapy. * To assess the effect of MCP on depression of BGC patients receiving chemotherapy. * To assess the effect of MCP on QoL and patients' satisfaction of BGC patients receiving chemotherapy. * To determine whether stress level, coping and coping styles mediate the intervention effect on anxiety, depression and QoL. Hypothesis * The participants receiving MCP will have a significantly lower level of anxiety compared to the control group. * The participants receiving MCP will have a significantly lower level of depression compared to the control group. * The participants receiving MCP will have significantly higher QoL scores and levels of satisfaction with care service compared to the control group. * Stress level, coping will mediate the intervention on target outcomes.

Registry
clinicaltrials.gov
Start Date
March 8, 2022
End Date
August 10, 2022
Last Updated
3 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Sponsor
The Nethersole School of Nursing
Responsible Party
Principal Investigator
Principal Investigator

Khanh Thi Nguyen

Principal Investigator

The Nethersole School of Nursing

Eligibility Criteria

Inclusion Criteria

  • Women with breast or gynaecological cancer are 18 years of age or older, and are independent legally to sign the consent form.
  • Living with family and having an adult family member agree to participate in the meeting part of the program.
  • Had been informed the cancer diagnosis
  • Have Karnofsky score (Mor et al., 1984) ≥ 80 ( to be able to self-practice MCP)
  • Can communicate, read and write in Vietnamese
  • Have a device such as a smartphone, MP3 to keep the audio file (to self-practice MCP at home)
  • Consent to join the study

Exclusion Criteria

  • The patients cannot understand the study procedures
  • Have mental health illness, deafness, blindness
  • Have not been aware of their cancer or the purpose of chemotherapy
  • Be participating in other studies related to psychological issues
  • Be receiving anxiety or depression treatment.
  • Be participating in relaxation therapy such as yoga, meditation, mindfulness, PMR...
  • Have a potential treatment (eg. surgery) or personal plans that will prevent them from practising daily during the 6 weeks of the intervention.

Outcomes

Primary Outcomes

Change from baseline anxiety at 3 weeks and 6 weeks

Time Frame: ebaseline, T1 after 3 weeks, T2 after 6 weeks

it will be measured using the short form of the Depression Anxiety Stress Scale (DASS-21). It includes 7 items for anxiety (DASS21-A). A 4-point Likert-type scale ranging from 0 to 3 was designed for each item, and the scores will need to be multiplied by 2 to calculate the final score. Thus, the anxiety score can range from 0 to 42. The higher the score is the more severe anxiety. The score of 0-7 is normal, 8-9 mild, 10-14 moderate, 15-19 severe, +20 extremely severe.

Change from baseline depression at 3 weeks and 6 weeks

Time Frame: baseline, T1 after 3 weeks, T2 after 6 weeks

it will be measured using the short form of the Depression Anxiety Stress Scale (DASS-21). It includes 7 items for depression (DASS21-D). A 4-point Likert-type scale ranging from 0 to 3 was designed on each item, and the scores will need to be multiplied by 2 to calculate the final score. Thus, the depression score can range from 0 to 42. The higher the score is the more severe depression. The score of 0-9 is normal, 10-13 mild, 14-20 moderate, 21-27 severe, +28 extremely severe.

Secondary Outcomes

  • Change from baseline quality of life at 3 weeks and 6 weeks(baseline, T1 after 3 weeks, T2 after 6 weeks)
  • Change from baseline stress at 3 weeks and 6 weeks(baseline, T1 after 3 weeks, T2 after 6 weeks)
  • Change from baseline coping styles at 3 weeks and 6 weeks(baseline, T1 after 3 weeks, T2 after 6 weeks)
  • Change from baseline satisfaction of nursing care at 3 weeks(baseline, T1 after 3 weeks,)

Study Sites (1)

Loading locations...

Similar Trials